Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.…
Abeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow
Abeona Therapeutics (NASDAQ: ABEO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 226 employees.
The shares were at 2.420 USD on 20 November 2026, down 51.5% over 52 weeks. Its 52-week range is 2.090 USD to 7.650 USD: the price is 68.4% below the high and 15.8% above the low.
Its market capitalisation is 165.31M USD.
Abeona Therapeutics reports return on equity of 44.7% and an operating margin of -186.1%.
It holds more cash than debt, a net cash position of 118.31M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 16 March 2027.